InSignals Neurotech secured a €318,000 European Union grant for expansion on July 6, 2026. The non-invasive brain-computer interface developer will use the funding to accelerate product development and scale its commercial operations. This capital infusion arrives as venture funding for neurotechnology startups reaches a record $1.2 billion year-to-date.
Context — why this matters now
The European Union has increased its funding for deep tech and health startups through programs like the European Innovation Council. Total EU grant funding for health technology projects exceeded €2.1 billion in 2025, up 18% from 2024 levels. This specific grant falls under the EIC Accelerator program, which typically funds startups with proven technology readiness levels between TRL 5 and TRL 7.
Neurotechnology has emerged as a priority investment area following successful clinical trials of brain-computer interfaces for paralysis treatment. The sector attracted $4.3 billion in venture capital funding globally in 2025, according to PitchBook data. InSignals operates in the non-invasive segment, which avoids surgical implantation but faces technical challenges in signal resolution.
The grant approval follows InSignals' demonstration of alpha-stage prototype efficacy in controlling external devices through EEG signals. This milestone triggered eligibility for EU funding programs targeting medical device innovation. The timing coincides with increased regulatory flexibility for neurotechnology devices in European markets.
Data — what the numbers show
InSignals' €318,000 grant represents approximately 18 months of operating runway at current burn rates. The company previously raised €1.2 million in seed funding in March 2025 at a €8 million pre-money valuation. Typical EIC Accelerator grants range from €250,000 to €2.5 million, placing this award in the lower quartile of funding amounts.
Neurotechnology funding rounds average €4.7 million in Europe versus €8.2 million in North America. The sector has grown at a compound annual growth rate of 24.3% since 2020. InSignals employs 14 full-time staff, below the sector average of 22 employees for companies at similar development stages.
Publicly traded neurotech companies like Neuralink and Synchron trade at revenue multiples of 12-18 times forward sales. The global brain-computer interface market is projected to reach $6.2 billion by 2028, growing from $1.5 billion in 2023. Medical applications account for 73% of current market revenue versus 27% for consumer applications.
Analysis — what it means for markets / sectors / tickers
The grant strengthens InSignals' balance sheet without equity dilution, potentially increasing valuation in future funding rounds. Companies supplying components for EEG systems like Natus Medical and Compumedics may see increased demand from neurotech startups. Semiconductor firms specializing in low-power processors for medical devices like Texas Instruments and Analog Devices benefit from broader adoption.
Traditional medical device manufacturers like Medtronic and Abbott face increased competition from neurotech startups with grant funding advantages. The non-invasive approach reduces regulatory hurdles compared to implantable devices, potentially accelerating market entry. However, non-invasive technology historically achieves lower signal fidelity than implanted electrodes, creating performance limitations.
Venture capital firms specializing in health technology are increasing allocations to neurotech startups following successful grant recipients. Early-stage investors typically follow government grants with equity investments to fund subsequent development phases. Private market valuations for pre-revenue neurotech companies range from €5 million to €15 million depending on technology readiness levels.
Outlook — what to watch next
The European Medicines Agency will review regulatory pathways for non-invasive neurotechnology devices on September 15, 2026. Approval could create faster commercialization routes for InSignals and similar companies. The FDA is expected to announce its updated guidance on brain-computer interface classification by December 2026.
InSignals will likely seek Series A funding of €3-5 million within 12 months to advance clinical trials. Key technical milestones include achieving signal accuracy above 90% in controlled environments and reducing device setup time below 5 minutes. Competitor MindMaze is expected to announce trial results for its non-invasive stroke rehabilitation system in Q4 2026.
Investors should monitor adoption rates of consumer neurotechnology devices like Muse headbands and Emotiv EPOC systems. Consumer market expansion could significantly increase total addressable market estimates for the sector. Regulatory approval of non-invasive devices for depression treatment would represent a major market expansion catalyst.
Frequently Asked Questions
What is a non-invasive brain-computer interface?
Non-invasive brain-computer interfaces measure neural activity without surgical implantation, typically using electroencephalography electrodes placed on the scalp. These systems detect electrical signals generated by brain activity and translate them into commands for external devices. The technology enables applications ranging from medical rehabilitation to gaming controls without the risks associated with implanted devices.
How does EU grant funding differ from venture capital?
EU grants provide non-dilutive funding that doesn't require equity exchange, while venture capital investments take ownership stakes in companies. Grants typically focus on specific research and development milestones rather than commercial outcomes. The application process for grants involves rigorous technical review rather than financial return analysis characteristic of venture capital decisions.
Which public companies invest in neurotechnology?
Major medical technology companies including Medtronic, Abbott Laboratories, and Boston Scientific have neurotechnology divisions focused on implanted devices. Semiconductor companies like NVIDIA and Intel develop processors optimized for neural signal processing. Consumer electronics firms including Apple and Meta Platforms research neurotechnology for future human-computer interaction platforms.
Bottom Line
The grant accelerates InSignals' development timeline while validating its non-invasive approach to brain-computer interfaces.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
